About US
Contact us
-
Vertex CEO faces growing pressure for pipeline deals despite major hike in Trikafta salesDuring last month’s J.P. Morgan healthcare conference, Vertex CEO Reshma Kewalramani, M.D., said the company is actively scouting for “tools and technology” to acquire, specifically mid- and late-sta2021/2/3
-
Fierce Pharma Asia—Lilly's COVID-19 antibody results, Asahi Kasei deal; Takeda's EGFR lung cancer dataEli Lilly said its two-drug COVID-19 antibody cocktail could prevent hospitalization or death among high-risk patients. The Indianapolis pharma in-licensed a neuroinflammatory pain candidate from Asa2021/2/1
-
FDA blasts Lonza facility in Form 483 that derailed Bristol Myers' plan of liso-cel nod by 2020A manufacturing shortfall likely cost Bristol Myers Squibb the chance of an FDA approval for CAR-T therapy liso-cel by the end of 2020—and sent a potential $9-apiece Celgene deal sweetener into the t2021/2/1
-
Pfizer's Xeljanz fails RA safety study, making a tough rivalry with AbbVie's Rinvoq even tougherPfizer has had a tough couple of years marketing its rheumatoid arthritis drug Xeljanz, as regulatory agencies have slapped warnings on the JAK inhibitor about potential cardiovascular side effects a2021/1/29
-
MIT spinout Continuus Pharmaceuticals nets $69M to onshore production of critical medsMassachusetts Institute of Technology (MIT) spinout Continuus Pharmaceuticals is joining the push to bring drug manufacturing stateside, and it's tappedsome cutting-edge tech for the job. Armed with2021/1/29
-
Johnson & Johnson is 'comfortable' meeting coronavirus vaccine delivery promises, CFO saysAs the world awaits Johnson & Johnson’s phase 3 COVID-19 vaccine data, the companyis prepping for regulatory filings and a global rollout.Orders for hundreds of millions of doses are pending. But2021/1/27
-
Nostrum Labs adds another NDMA-tainted metformin lot to its growing recall2020's metformin recalls have bled into the new year. Just this week, Nostrum Laboratories, which already extended a product pull earlier this month, put another lot on the chopping block thanks to f2021/1/27
-
Novartis set to answer inclisiran's FDA rebuff by Q3. But what about an approval timeline?Novartis bought cholesterol drug inclisiran on the brink of a new drug filing as the centerpiece of its $9.7 billion acquisition of The Medicines Company. But, in the wake of an FDA rebuff amid the p2021/1/25
-
Moderna to test different booster shot against South Africa coronavirus variantModerna is weighing a second booster shot to battle back a new coronavirus variant, even as it affirms its current vaccine's activity against newly emerging mutants. While the current two-dose regime2021/1/25
-
The top 10 largest biopharma M&A deals in 2020Biopharma M&A activities suffered a slowdown in 2020. One could argue that 2019’s megadeals consumed some of last year’s quota, and COVID-19 definitely didn’t help. But AstraZeneca’s $39 billio2021/1/20